Abstract: Provided herein are scalable methods of processing wet-spun fiber comprising recombinant spider silk polypeptides to generate a three-dimensional crystalline lattice of beta-sheet structures in the fiber.

Abstract: A polar solvent solution of the present invention is a polar solvent solution in which a solute containing a polyamine acid is dissolved in a polar solvent. The solution has a moisture content of less than 5 mass % based on 100 mass % of the solution. A method for producing a polar solvent solution of the present invention includes changing a moisture content of the solution to adjust the viscosity of the solution. Further, another method for producing a polar solvent solution includes reducing a moisture content of the solution to increase the viscosity of the solution. Thus, the present invention provides a polar solvent solution that enables stable spinning and casting without lowering its viscosity when used as dopes for spinning, film, etc., and methods for producing the same.

Abstract: The present invention relates to a method for manufacturing a protein fiber, including an extension and contraction step of contracting or extending a protein raw fiber containing a protein by bringing the protein raw fiber into contact with a liquid or vapor; and a drying step of drying the protein raw fiber that has undergone the extension and contraction step while adjusting a length of the protein raw fiber to an arbitrary length.

Abstract: Provided is a molded article of a composition comprising a polypeptide, wherein the polypeptide is at least one kind selected from the group consisting of natural spider silk protein and polypeptides derived from natural spider silk protein.

Abstract: An object of the present invention is to provide a method for efficiently separating insoluble bodies of a recombinant protein from a recombinant cell expressing a target recombinant protein as insoluble bodies in the cell. The present invention provides a method for producing a recombinant protein aggregate by separating insoluble bodies of a recombinant protein from a recombinant cell expressing the recombinant protein as insoluble bodies in the cell, including disrupting the recombinant cell, aggregating the insoluble bodies of the recombinant protein, and separating the resulting aggregate.

Abstract: The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer.

Abstract: Provided is a method of bioassay for the quantification of peptide fragments elevated in lung diseases such as COPD, SCC, or IPF. The peptide fragments comprise a neo-epitope formed at a cleavage site by cleavage in vivo of elastin by a proteinase. In the method a sample is contacted with an antibody having specific binding affinity for the neo-epitope amino acid sequence and determining the level of binding is determined where the antibody binds one of the following terminal sequences: . . . FGPGVV, . . . VPGLGV or IKAPKL . . . . Also provided are antibodies and immunoassay kits for use in such methods.

Abstract: The disclosure provides ceramic materials comprising calcium phosphate material and silk and processes and methods for preparing and uses thereof.

Abstract: The invention provides a method for the controlled assembly of layered silk fibroin coatings using aqueous silk fibroin material. The methods described herein can be used to coat substrates of any material, shape, or size. Importantly, the described methods enable control of the biomaterial surface chemistry, thickness, morphology and structure using layered thin film coatings, or bulk coatings. Furthermore, the methods can be performed in all water and do not require intensive chemical processing enabling controlled entrapment of labile molecules such as, drugs, cytokines, and even cells or viruses to generate functional coatings that can be used in a variety of applications.

Abstract: The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering of 3-dimensional tissue, e.g. bone and cartilage, using the silk fibroin scaffold material are also provided.

Abstract: A solution-dyed protein fiber of the present invention includes 0-100 mass % of silk fibroin and 100-0 mass % of a polypeptide derived from spider silk proteins when the protein fiber is assumed to be 100 mass %, wherein the solution-dyed protein fiber contains a solution-dyeing colorant. The fiber is obtained by: dissolving or dispersing a solution-dyeing colorant in a solvent used for a spinning solution or in dimethyl sulfoxide, thereby preparing a coloring liquid; adding a solvent to the coloring liquid in an amount necessary for a spinning solution; adding and dissolving protein powder into the solvent, thereby preparing a spinning solution; and subjecting the spinning solution to wet spinning or dry-wet spinning. Thereby, the present invention provides a low-cost solution-dyed protein fiber in which a solution-dyeing colorant is dispersed uniformly and that can exhibit bright color tone, and a method for producing the same.

Abstract: This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.

Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.

Abstract: A recombinant fusion protein comprising the moieties Band CT, and optionally REP, wherein B is comprising at least one immunoglobulin fragment, which provides the capacity of selective interaction with an organic target; CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein; and REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein.

Abstract: A method for obtaining silk extract containing lutein according to an embodiment of the invention is described. The lutein extraction method uses a three solvent system for extracting bioactive lutein from silk fibers. The extracted lutein has more than 95% purity in all-E isomer with biological activity being 5 times more effective on lipid peroxidation in retina cells and twice immune stimulation in mice when compared with commercially available lutein.

Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement ac

Abstract: A silk fiber based matrix composition comprising spider silk that can be biodegradable, from the spider species Nephila clavipes (or from genetically engineered bacteria making Nephila clavipes silk), and in the form of a mesh or film.

Abstract: The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.

Abstract: Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.

Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Abstract: The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.

Abstract: A recombinant fusion protein comprising the moieties Band CT is provided. B is a non-spidroin moiety which provides the capacity of selective interaction with an organic target. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. The fusion protein is not comprising any moiety derived from the repetitive fragment of a spider silk protein.

Abstract: A chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight water-soluble elastin and coupling some or all of the carboxyl groups contained in the molecule with the amino group of an amino acid alkyl ester. A chemically modified water-soluble elastin/collagen mixed gel obtained by mixing a collagen with a chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight water-soluble elastin and coupling some or all of the carboxyl groups contained in the molecule with the amino group of an amino acid alkyl ester.

Abstract: A method for making natural fibre products comprising embrittling natural fibres and breaking the embrittled fibres into nanoparticles, forming a suspension of the fibre nanoparticles in a spinnable liquid, and spinning fibre from the suspension. The method may be used to make fibres having the dimensions and properties of cashmere.

Abstract: There are provided a recombinant silk protein derived from sea anemones, a method for producing the same, and a composition for preparing a silk fiber including same. The recombinant silk protein derived from sea anemones has sequence features similar to genetic information of a silk protein derived from spiders and silkworms. Also, a large amount of recombinant silk protein derived from sea anemones may be produced from a transformant and it has good physical properties such as strength and elasticity. Therefore, the recombinant silk protein derived from sea anemones can be usefully applied in various industrial fields in which natural silk protein can be applied, and it is expected to create new industrial fields based on its distinctive mechanical properties.

Abstract: A method for solubilizing recombinant spider silk proteins in an aqueous solutions, where the method includes mixing recombinant spider silk proteins with water to form a mixture and heating the mixture in a closed vessel to form a solution.

Abstract: The disclosure provides spider silk polypeptides and polynucleotides encoding the same. Methods of using such polypeptides and polynucleotides and designing novel biomaterials using repeat units of the polypeptides and polynucleotides.

Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: The present disclosure provides methods for fabricating various regenerated silk geometries using temperature control. In addition to temperature control, mechanical processing can be used to enhance properties of the fabricated article. The present disclosure also provides silk foam and paper-like materials molded using freezer processing.

Abstract: A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described.

Abstract: A method of manufacturing a biopolymer optofluidic device including providing a biopolymer, processing the biopolymer to yield a biopolymer matrix solution, providing a substrate, casting the biopolymer matrix solution on the substrate, embedding a channel mold in the biopolymer matrix solution, drying the biopolymer matrix solution to solidify biopolymer optofluidic device, and extracting the embedded channel mold to provide a fluidic channel in the solidified biopolymer optofluidic device. In accordance with another aspect, an optofluidic device is provided that is made of a biopolymer and that has a channel therein for conveying fluid.

Abstract: In one aspect, the invention provides a method for making a hydrophilic-silk composition. The method includes providing at least one strand of silk fiber, treating the silk fiber with an alkaline solution to provide at least one strand of degummed silk fiber, and treating the degummed silk fiber with a treatment solution to provide a hydrophilic-silk composition. The degummed silk fiber or the hydrophilic-silk composition is further immobilized with at least one reagent to make a silk-based diagnostic composition. The invention provides a silk-based diagnostic composition made by the method of the invention, and a diagnostic device that comprises the silk-based diagnostic composition. In another aspect, the invention provides a method of making a diagnostic device.

Abstract: Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions.

Abstract: The inventions provided herein relate to compositions, methods, delivery devices and kits for repairing or augmenting a tissue in a subject. The compositions described herein are injectable such that they can be placed in a tissue to be treated with a minimally-invasive procedure (e.g., by injection) and/or be molded flexibly into a tissue void of any shape and/or size. In some embodiments, the composition described herein comprises a plurality of silk fibroin particles, which can retain their original volume within the tissue for a period of time. The compositions can be used as a filler to replace a tissue void, e.g., for tissue repair and/or augmentation, or as a scaffold to support tissue regeneration and/or reconstruction. In some embodiments, the compositions described herein can be used for soft tissue repair or augmentation.

Abstract: This invention provides for a process of rapidly forming silk fibroin gelation through ultrasonication. Under the appropriate conditions, gelation can be controlled to occur within two hours after the ultrasonication treatment. Biological materials, including viable cells, or therapeutic agents can be encapsulated in the hydrogels formed from the process and be used as delivery vehicles.

Abstract: In an embodiment, a number of synthetic protein triblock copolymers are provided comprising first and second end hydrophobic blocks separated by a central hydrophilic block. In particular, the synthetic proteins are elastin-mimetic proteins having improved mechanical characteristics and related methods of making the proteins with the capability of providing precise control over the mechanical properties. Provided are proteins used in a number of medical devices such as artificial blood vessels, shunts, stents or as embolic agents in situations where it is desired to stop or reduce blood flow or pressure in a localized region.

Abstract: The present invention relates to silk proteins which can be used to produce silk with a collagen-like structure, as well as nucleic acids encoding such proteins. The present invention also relates to recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the production of personal care products, plastics, textiles, and biomedical products.

Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistence in the body, solubility, and bioavailability.

Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.

Abstract: A polypeptide solution of the present invention is a polypeptide solution in which a polypeptide derived from natural spider silk proteins is dissolved in a solvent. The solvent contains at least one selected from the following (i)-(iii): (i) DMSO; (ii) DMSO with an inorganic salt; and (iii) DMF with an inorganic salt. Further, in the present invention, an artificial polypeptide fiber is obtained by: using the polypeptide solution as a dope solution; and extruding the dope solution from a spinneret into a desolvation bath so as to eliminate the solvent from the dope solution and form a fiber to produce an undrawn yarn. Moreover, in the present invention, a polypeptide is purified by subjecting the polypeptide solution to heat treatment and thereafter removing an undissolved substance therefrom.

Abstract: Provided is a three-dimensional flat cocoon product which is lightweight, has a favorable design and yields a highly uniform flat cocoon throughout the entire area thereof. The method of producing a flat cocoon product includes: expanding an expandable/contractible three-dimensional molding die; molding a flat cocoon by causing silkworms to crawl on an outer surface of the three-dimensional molding die and spin a cocoon; and contracting the three-dimensional molding die after the molding of the flat cocoon and extracting the contracted three-dimensional molding die from the flat cocoon.

Abstract: A method of manufacturing a biopolymer photonic crystal includes providing a biopolymer, processing the biopolymer to yield a biopolymer matrix solution, providing a substrate, casting the matrix solution on the substrate, and drying the biopolymer matrix solution to form a solidified biopolymer film. A surface of the film is formed with a nanopattern, or a nanopattern is machined on a surface of the film. In another embodiment, a plurality of biopolymer films is stacked together. A photonic crystal is also provided that is made of a biopolymer and has a nanopatterned surface. In another embodiment, the photonic crystal includes a plurality of nanopatterned films that are stacked together.

Abstract: A chemoembolic agent is disclosed that includes an injectable, recombinantly synthesized silk-elastin like protein copolymer and one or more chemotherapeutic agents. Upon injection, the chemoembolic agent blocks the tumor vasculature, including the capillary bed, and may optionally release chemotherapeutic agents. The chemoembolic agent may be used to treat cancer, including hepatocellular carcinoma.

Abstract: The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in shape for easy application to the ocular surface. The silk film may either self-adhere or be sutured to cover the wound. The degradation time of the film may range from 1 minute to 24 hours, or from 2 hours to 20 hours. The present compositions can help regenerate damaged corneal tissue, thus promoting healing.

Abstract: Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.

Abstract: The invention provides compositions and methods for reversible covalent binding of benefit agents to keratinous substrates through the reaction of a dicarbonyl functional group on the surface of a benefit agent with reactive amines on keratinous surfaces. The deposits formed are durable and resistant to transfer, but are readily removed by contacting the deposit with an amine-containing solution.

Abstract: The invention relates to methods and compositions for preparing silk-based piezoelectric materials and methods for increasing piezoelectricity in silk matrices.

Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

Abstract: The present invention is directed to a method of producing nano- and microcapsules from spider silk proteins The invention is further directed to nano- or microcapsules obtainable by this method as well as pharmaceutical, cosmetical and food compositions containing same.

Abstract: This invention provides for compositions, methods and devices for rapidly converting silk fibroin solution into a silk fibroin gel using direct application of voltage, in a process called electrogelation. The silk fibroin gel may be reversibly converted back to liquid form by applying reverse voltage or may be converted further to ?-sheet structure by applying shear force or other treatments. The electrogelated silk may be used as an extracted bulk gel, spray or stream of gel for processing into materials or devices, or may be used as silk gel coating to devices. Active agents may be embedded in the silk gel for various medical applications. This invention also provides for methods and compositions for preparing adhesive silk pH-gels. For example, the method comprises reducing pH level of a silk fibroin solution to increase the bulk or local proton concentration of the silk fibroin solution, thereby forming adhesive silk gels.